SCHEMBL10101562

SCHEMBL10101562

C[C@H]1[C@H](O)[C@H](c2cc(F)c3c(N)ncnn23)O[C@@H]1CO

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACVRL1 P37023 15/20 0.40
▸ DPP4 P27487 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ SLC28A1 O00337 1/20 0.35
▸ MAP3K7 O43318 1/20 0.35
▸ SLC28A2 O43868 1/20 0.35
▸ GAPDH P04406 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ STAT6 P42226 1/20 0.35
▸ PI4KA P42356 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PI4K2B Q8TCG2 1/20 0.35
▸ DOT1L Q8TEK3 1/20 0.35
▸ SLC29A1 Q99808 1/20 0.35
▸ PI4K2A Q9BTU6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10101499 0.89 ACVRL1 (0.38) ACVRL1
SCHEMBL10101563 0.89 ACVRL1 (0.38) ACVRL1
SCHEMBL10101558 0.87 ADK (0.35) ACVRL1DPP4MEN1SLC28A1MAP3K7
SCHEMBL10101568 0.87 PIK3CD (0.36) ACVRL1DPP4MEN1SLC28A1MAP3K7
SCHEMBL10101588 0.84 HIF1A (0.35) ACVRL1DPP4MEN1SLC28A1MAP3K7
SCHEMBL10101583 0.84 NPC1 (0.40) ACVRL1DPP4MEN1SLC28A1MAP3K7
SCHEMBL10101575 0.84 CSNK2A2 (0.34) ACVRL1DPP4MEN1SLC28A1MAP3K7
SCHEMBL10101611 0.84 DOT1L (0.40) ACVRL1DPP4MEN1SLC28A1MAP3K7
SCHEMBL10101578 0.84 KDM4E (0.36) ACVRL1DPP4MEN1SLC28A1MAP3K7
SCHEMBL10101603 0.83 ACVRL1 (0.33) ACVRL1DPP4MEN1SLC28A1MAP3K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119607-B2 Bicyclic nucleosides and nucleotides as therapeutic agents BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-02-21 — — US disclosed
US-20100035836-A1 BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS BIOTA SCIENTIFIC MANAGEMENT (AU) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035836-A1 BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS NTPCR, PNP, DCTD ACVRL1 4215/4885DPP4 2030/4885MEN1 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback